|
Transgenomic acquires clinical sample biorepository from Gene Logic
July 2012
SHARING OPTIONS:
OMAHA, Neb.—Transgenomic Inc. announced last month that it
has entered into an agreement with Gene Logic Inc., an Ocimum Biosolutions
company, to acquire its biorepository assets for $250,000 in cash. The
biorepository contains thousands of human biological samples that can be used
to validate diagnostic assays developed by Transgenomic.
Transgenomic will use the samples to develop and validate
its REVEAL family of proprietary ICE COLD-PCR-based
oncology assays, as well as
its WAVE MCE System and SURVEYOR Scan Mutation Detection Kits.
The
Gene Logic biorepository consists of a high-quality,
diverse collection of human tissue samples and extracted DNA specimens with
linked clinical
information. The 60,000 samples and specimens cover multiple
disease areas, including many thousands of cancer tissue specimens.
"This transaction significantly strengthens Transgenomic's
position in translational medicine services, providing
a deep source of
clinical samples allowing us to validate new drug-associated genetic targets,"
said Craig Tuttle, CEO of Transgenomic. "The
biorepository provides not only
strategic and operational benefits, but also long-term cost savings. Acquiring
specimens on a case-by-case basis is
expensive and time-consuming; such
expenditure would quickly surpass the cost of acquiring this asset." Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|